Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
CompletedNCT01192165
GlaxoSmithKlineCancer
Start: 2010-09-14End: 2013-10-07Updated: 2017-11-13